Compare STKS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | CING |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 64.5M |
| IPO Year | 2011 | 2021 |
| Metric | STKS | CING |
|---|---|---|
| Price | $1.83 | $5.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.70 | ★ $34.50 |
| AVG Volume (30 Days) | 16.4K | ★ 146.4K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $7.47 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.65 | $3.16 |
| 52 Week High | $3.38 | $11.89 |
| Indicator | STKS | CING |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 46.89 |
| Support Level | $1.69 | $4.80 |
| Resistance Level | $1.97 | $5.20 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 77.27 | 51.57 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.